Galapagos presents clean drug-drug interaction profile with

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Galapagos presents clean drug-drug interaction profile with GLPG0634 (filgotinib) at ACR 2014

MECHELEN, Belgium, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext: GLPG), a clinical stage biotech company focused on developing novel mode of action medicines, announces that it will present data supporting the safe use and absence of drug-drug interactions of GLPG0634 (filgotinib) with drugs commonly prescribed for rheumatoid arthritis (RA) patients. In addition, Galapagos will show support for the dose selection in the Phase 2B DARWIN program and present the reversals of RA disease gene expression in patients treated with GLPG0634. These data will be presented at the ACR/ARHP Annual Meeting, November 14 - 19, in Boston, Massachusetts.

GLPG0634 is an orally-available, selective JAK1 inhibitor. Selective inhibition of JAK1 may combine favorable safety and clinical efficacy profiles with rapid onset of action. GLPG0634 is currently in a global Phase 2B program (DARWIN) in 875 RA patients and in a Phase 2 study in 180 patients with Crohn's disease.

All three posters on GLPG0634 will be presented during the ACR poster session entitled: "Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Novel therapies, Biosimilars, Strategies and Mechanisms in Rheumatoid Arthritis," from 9 - 11 AM EST on Monday, 17 November, 2014. The posters are also available on the Galapagos home page, www.glpg.com . Below are summaries of the key findings in each poster:

"Phase 1 and Phase 2 Data Confirm That GLPG0634, a Selective JAK1 Inhibitor, Has a Low Potential for Drug-Drug Interactions" Abstract #1481

In contrast to some other JAK inhibitors, GLPG0634 does not interact with CYP450s and drug transporters. In vitro data are confirmed by clinical data in healthy volunteers and RA patients showing that GLPG0634 does not inhibit neither induce CYP3A4 activity. GLPG0634 also shows no interaction with OAT transporters involved in methotrexate or statin excretion. Taken together, these data suggest that GLPG0634 can be used safely without dose adjustment in RA-patients treated with frequently co-administered drugs such as methotrexate and statins.

"Dose Selection of GLPG0634, a Selective JAK1 Inhibitor, for Rheumatoid Arthritis Phase 2B Studies: PK/PD and Exposure-DAS28 Modelling Approach" Abstract #1480

A PK/PD modelling analysis show that GLPG6034 and its main metabolite both contribute to the pSTAT1 biomarker response. A DAS28 clinical response model highlights a dose-response relation with a maximum efficacy achieved at a daily dose of 200 mg GLPG0634. No further gain is obtained at higher doses. The overall clinical response, as measured by DAS28, is in the range of that observed with registered biological DMARDS. A GLPG0634 daily dose range from 50 to 200 mg is currently being tested in the Phase 2B DARWIN program.

"Treatment of Rheumatoid Arthritis Patients with the JAK1-Selective Inhibitor GLPG0634 Reverses an Arthritis-Specific Blood Gene Signature to Healthy State" Abstract #1494

An RA-specific gene signature was found in circulating white blood cells. Treating RA patients with GLPG0634 was associated with a reversal of the gene expression, resulting in a gene signature similar to healthy volunteers. These data support the clinical efficacy observed in the phase 2A study and thus expand our knowledge of the effects of GLPG0634 in RA patients.

About Galapagos

Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action, with a pipeline comprising three Phase 2 studies, two Phase 1 studies, five pre-clinical, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, antibiotics and metabolic disease. In the field of inflammation, AbbVie and Galapagos signed an agreement for the development and commercialization of GLPG0634. GLPG0634 (filgotinib) is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and other inflammatory diseases, currently in Phase 2B studies in RA and in Phase 2 in Crohn's disease. Galapagos has another selective JAK1 inhibitor, GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in 2012). AbbVie and Galapagos signed an agreement in cystic fibrosis to develop and commercialize molecules that address mutations in the CFTR gene. Potentiator GLPG1837 is expected to start Phase 1 in 2014. Galapagos also expects to nominate a pre-clinical candidate corrector before year end 2014. The Galapagos Group, including fee-for-service subsidiary Fidelta, has around 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. Further information at: www.glpg.com

CONTACT

Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications & IR
Tel: +31 6 2291 6240

ir@glpg.com

Galapagos forward-looking statements

This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

HUG#1871734

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rehab Equipment Growth Meets a Brutal Access Gap

Updated Category News Views 89

Rehabilitation demand is piling up faster than the equipment can reach people. That is the uncomfortable fact sitting beneath Wissen Research's forecast for a global rehabilitation equipment market rising from $19.1 billion in 2026 to $25.8 billion by 2031, a 6.2% annual growth rate. It is a respectable expansion story, not some rocket-ship fairy tale. More important, it...

Continue Reading
Precision Metal Forming Is Industry's Quiet Backbone

Updated Category News Views 88

A fraction of a millimeter can turn a perfectly good industrial part into an expensive headache. That unglamorous reality sits at the center of Michele Caulfield's discussion of precision metal forming for HelloNation, and it deserves more attention than it usually gets. Investors watching manufacturing tend to chase flashy automation headlines, big aerospace orders, or...

Continue Reading
A Parish Memoir That Sends Its Proceeds Back Home

Updated Category News Views 114

Some books arrive with a thunderclap; this one shows up carrying a folding chair, a prayer book, and a memory that refuses to leave. You Give Them Something to Eat, the new memoir from Fr. Michael J Rieder, is built from more than a hundred short chapters rather than one grand, polished life story. That choice fits the material. Parish life is rarely a clean parade of...

Continue Reading
DocLinq Takes Aim at Care Gaps Between Office Visits

Updated Category News Views 149

Healthcare's most expensive loose ends often pile up after the appointment ends. DocLinq, launched from Columbia, Maryland, is taking a run at that awkward stretch between office visits, where records sit in separate systems, chronic-care follow-up gets uneven, and patients are expected to remember far more than any human reasonably can. This is not a story about AI...

Continue Reading
Parents Hand Kids Devices Years Before They Intended

Updated Category News Views 286

A nine-year-old with a smartphone used to raise eyebrows; this survey says it is increasingly the household baseline. All About Cookies, working with parental-control company Bark, surveyed U.S. parents and found that children typically receive personal devices well before their parents believe they should. That mismatch is not some cute little parenting contradiction. It...

Continue Reading
CloudBackend's €6.6M Test: Can Vibe Code Become SaaS?

Updated Category News Views 108

A prototype is cheap theatre; keeping it alive after customers arrive is where the bill lands. CloudBackend has raised €6.6 million to attack that unglamorous, absolutely vital stretch between an AI-made app and an actual software business. The round is led by Carl-Henric Svanberg's family office, while existing backer M2 Asset Management increased its stake. That is a...

Continue Reading
Snowrise Targets the Blind Spots in CPG Sales Data

Updated Category News Views 128

A sales total can look healthy while the floorboards are quietly rotting underneath it. That is the uncomfortable CPG problem Snowrise is aiming at: brands know what moved last quarter, but often cannot identify which stores, channels, communities, or promotions actually created the result. Plenty of management teams still steer by topline revenue, net distribution gains,...

Continue Reading
Hanmi Compressor Tests Vietnam Before Wider Expansion

Updated Category News Views 125

Compressed air is the sort of factory necessity nobody brags about until it fails, and that is precisely why Hanmi Compressor’s Vietnam plan deserves a sober look. The Daegu-based specialist is not arriving with a grand export victory lap. It is still building the front door: a website, a promotional video, and a process for finding Vietnamese manufacturers and...

Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion

Updated Category News Views 36

Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...

Continue Reading
Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 117

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading

Top 5 Most Recently Viewed Articles

Current Trends in Short Interest Impacting PayPal Stock

Updated Category News Views 262

Understanding PayPal Holdings Inc and Its Market Position PayPal Holdings Inc (NYSE: PYPL) remains a prominent player in the digital payments space, continuing to see fluctuations in its market sentiment. Recently, the company has noted a significant increase in short interest as a percentage of float, climbing by 11.57%. This rise has brought the total number of shares...

Continue Reading
WillScot Plans Upcoming Earnings Call and Webcast for Q1

Updated Category News Views 152

WillScot Holdings Corporation to Share Q1 Results WillScot Holdings Corporation, a renowned leader in providing innovative temporary flexible space solutions, has announced its schedule for releasing the financial results for the first quarter of 2025. This eagerly anticipated announcement is set to take place on May 1, 2025, after market close, allowing investors and...

Continue Reading
Denarius' Bold Move: Debentures Target Early Exit

Updated Category News Views 53

Treading Against Debentures: Denarius' Maneuver Denarius Metals Corp. doesn't seem keen on playing it safe with convertible debentures tying up its business. Jaw-dropping numbers in news like this make you stop and wonder: Is this strategy brilliance, or just a roll of the dice? Time-Pressured Decisions Denarius Metals, trading as OTCQX: DNRSF, has kicked off a whirlwind...

Continue Reading
Katten Partners Recognized Among Top Experts in Crypto Sector

Updated Category News Views 185

Katten Partners Shine in Crypto Industry Recognition Katten, a well-respected law firm, has gained significant attention for its leadership in the evolving digital asset landscape. Three of its distinguished partners have been recognized by Citywealth, a leading publication in the private wealth sector, for their exceptional contributions to the cryptocurrency domain. The...

Continue Reading
Anticipating Logitech International's Earnings Success

Updated Category News Views 160

Anticipating Logitech International's Earnings Success Logitech International (NASDAQ: LOGI) is gearing up for its next quarterly earnings announcement, and investors are keenly observing potential developments. As the company prepares to report earnings, expectations are high for positive news regarding financial forecasts and results. Analyst Predictions for Earnings...

Continue Reading